EGFR and neoplasm: No objective responses were noted in the 11 patients treated with erlotinib and onalespib (10 EGFRex20ins and one EGFR E19del), although half of the patients (5/10) with EGFRex20ins treated with erlotinib and onalespib had some degree of tumor shrinkage (Figure 2).